Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | KCNQ3 | O43525 | 4/20 | 0.40 |
| ▸ | KCNQ2 | O43526 | 4/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.36 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ECE1 | P42892 | 1/20 | 0.36 |
| ▸ | USP7 | Q93009 | 1/20 | 0.35 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL875494 | 0.86 | KDM4E (0.50) | HPGDGAAMAPTTP53KCNQ2 | |
| SCHEMBL876309 | 0.85 | KCNQ2 (0.36) | SMN1; SMN2MAPTTP53KCNQ3KCNQ2 | |
| SCHEMBL883428 | 0.84 | SMN1; SMN2 (0.40) | SMN1; SMN2CYP1A2CYP2C9HPGDCYP3A4 | |
| SCHEMBL876306 | 0.84 | SMN1; SMN2 (0.40) | SMN1; SMN2CYP1A2CYP2C9HPGDCYP3A4 | |
| SCHEMBL883352 | 0.81 | KCNQ3 (0.37) | SMN1; SMN2CYP1A2CYP2C9HPGDCYP3A4 | |
| SCHEMBL883703 | 0.69 | LMNA (0.44) | SMN1; SMN2HPGDGAAMAPTTP53 | |
| SCHEMBL883609 | 0.69 | KCNQ2 (0.35) | KCNQ3KCNQ2KCNQ4KCNQ5 | |
| SCHEMBL15106118 | 0.69 | KCNQ2 (0.36) | SMN1; SMN2MAPTKCNQ3KCNQ2POLB | |
| SCHEMBL875869 | 0.68 | USP7 (0.38) | SMN1; SMN2CYP1A2CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL10074404 | 0.67 | KDM4E (0.49) | SMN1; SMN2HPGDGAAMAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2619202-A1 | PYRIDMIDONES FOR TREATMENT OF POTASSIUM CHANNEL RELATED DISEASES | Pfizer Inc (US) | 2013-07-31 | — | — | EP | disclosed |
| US-20130184294-A1 | Pyrimidones for Treatment of Potassium Channel Related Diseases | PFIZER INC. (US) | 2013-07-18 | — | — | US | disclosed |
| WO-2012038850-A1 | PYRIDMIDONES FOR TREATMENT OF POTASSIUM CHANNEL RELATED DISEASES | PFIZER INC. (US) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184294-A1 | Pyrimidones for Treatment of Potassium Channel Related Diseases | KCNQ5, KCNQ1, KCNQ3 | SMN1; SMN2 912/4885CYP1A2 916/4885CYP2C9 921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.